Acute Lymphocytic Leukemia (ALL), also known as the cancer of white blood cells crowds out normal cells in the bone marrow, which later spreads on to different organs. This disease can cause severe organ damage to death of the patient, which makes it life threatening. The instances of this disease are higher in the children in the age group 0 to 14, than those aging above 15. Cure and management of this ALL is a realistic goal, which requires constant supply of medication and medical care consisting of various therapies and drugs. The acute lymphocytic leukemia therapeutics market has made strong growth in the past few years, majorly because of the sudden rise in the number of cases recorded with ALL across the world. Innovative treatments also play vital role in the growth of the global industry for ALL therapeutics.
Global Acute Lymphocytic Leukemia Therapeutics Market is segmented on the basis of the types of the disease, drugs and demand from different regions of the world. Childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia are the two basic categories in the market. Both these categories are analyzed based on the types of drugs used for their treatment. Geographic significance and demand for different drugs are also observed. The drugs segments in ALL therapeutics industry is segmented into two major types, which include existing regimen and pipeline drugs, which are used in the phase III of the disease.
- Existing Regimen: Linker, Hyper-CVAD, CALGB 8811, Oncaspar and Nucleoside metabolic inhibitors
- Pipeline Drugs: Marqibo, Graspa and Inotuzumab Ozogamicin
Apart from the types of drugs, the industry is also segmented on the basis of geographic regions, which include North America, Europe and Japan.
- North America: US and Canada
- Europe: France, Germany, Italy, Spain and UK
Market Drivers and Forecasting by 2018
Increasing occurrences of acute lymphocytic leukemia is the strongest drive for the acute lymphoblastic leukemia therapeutics market. Apart from that, innovative technologies in terms of treatment and therapeutic relief from ALL also hold significant influence on the growth in the industry. Expiration of patents is the expected to be the strongest challenge for the industry. Overall, researchers are expecting steady progress for the global ALL therapeutics market. According to the market research reports, acute lymphocytic leukemia therapeutics market is expected to grow at a CAGR of over 4% from 2015 to 2020. During the forecasting period, the market is anticipated to become worth $3,780.3 million by 2020. In 2013, the industry was worth $2,777.2 million. Europe and North America are currently dominating the industry.